Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Giuliano, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Giuliano, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview

F. Giuliano1

Department of Urology, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France

1 Correspondence: François Giuliano, MD, PhD, Department of Urology, CHU de Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre Cedex, France.

Abstract

Widely distributed throughout the body, cyclic nucleotide phosphodiesterases (PDEs) are functionally heterogeneous enzymes with potential roles in a number of physiological actions. Among these enzymes, PDE type 5 has received particular attention because of the widespread use of the PDE5 inhibitor sildenafil citrate as an oral therapy for erectile dysfunction. Within the corpus cavernosum of the penis, PDE5 catalyzes the enzymatic degradation (inactivation) of cyclic 3',5'-guanosine monophosphate, which is a second messenger and key mediator of vascular and trabecular erectile tissue smooth muscle relaxation. By amplifying the nitric oxide-cyclic nucleotide signalling pathway, PDE5 inhibitors serve as ‘contingent agonists’ of the physiological response to sexual arousal. In experimental models, tadalafil increased the sensitivity of penile resistance arteries and erectile tissues to three stimuli of smooth muscle relaxation, namely electrical field stimulation, sodium nitroprusside, and acetylcholine. In randomized, double-blind, placebo-controlled trials, sildenafil and the investigational agents tadalafil and vardenafil significantly enhanced erectile function in the majority of patients and were well tolerated.

Key Words: Erection • nitric oxide • phosphodiesterase type 5 inhibitors • sildenafil citrate • tadalafil • vardenafil

References

  1. Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract. 2001;55:115–128[ISI][Medline]
  2. Brock GE, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–1336[CrossRef][ISI][Medline]
  3. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192–199[CrossRef][ISI][Medline]
  4. Goldstein I. Male sexual circuitry. Working Group for the Study of Central Mechanisms in Erectile Dysfunction. Sci Am. 2000;283:70–75
  5. Rehman J, Melman A. Pathophysiology of erectile dysfunction. Lue TF, Goldstein M. Impotence and Infertility. Philadelphia, Pennsylvania: Current Medicine Inc; 1999. p. 1.1–1.16
  6. Giuliano F, Rampin O, Brown K, Courtois F, Benoit G, Jardin A. Stimulation of the medial preoptic area of the hypothalamus in the rat elicits increases in intracavernous pressure. Neurosci Lett. 1996;209:1–4[CrossRef][ISI][Medline]
  7. Giuliano F, Rampin O. Central neural regulation of penile erection. Neurosci Biobehav Rev. 2000;24:517–533[CrossRef][ISI][Medline]
  8. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326:90–94[Abstract]
  9. Angulo J, Gadau M, Fernandez A, et al. IC351 enhances NO-mediated relaxation of human arterial and trabecular penile smooth muscle. [abstract 415]Eur Urol. 2001;39(suppl 5):106
  10. Sáenz de Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res. 2000;12(suppl 4):S34–S38
  11. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol. 2000;184:409–420[CrossRef][ISI][Medline]
  12. Sullivan ME, Thompson CS, Dashwood MR, et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease. Cardiovasc Res. 1999;43:658–665[Abstract/Free Full Text]
  13. Mizusawa H, Hedlund P, Brioni JD, Sullivan JP, Andersson KE. Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol. 2002;167:2276–2281[CrossRef][Medline]
  14. Saenz de Tejada I, Blanes R, Goldstein I, et al. Cholinergic neuro-transmission in human corpus cavernosum: I. Responses of isolated tissue. Am J Physiol. 1988;254:H459–H467
  15. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol. 2001;65:1–52[ISI][Medline]
  16. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1996;36:403–427[CrossRef][ISI][Medline]
  17. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725–748[Abstract/Free Full Text]
  18. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, et al. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest. 1997;100:2611–2621[ISI][Medline]
  19. Fawcett L, Baxendale R, Stacey P, et al. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDEIIA. Proc Natl Acad Sci USA. 2000. p. 3702–3707
  20. Montorsi F, McDermott TE, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 1999;53:1011–1018[CrossRef][ISI][Medline]
  21. Olsson AM, Speakman MJ, Dinsmore WW, et al. Sildenafil citrate (Viagra) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract. 2000;54:561–566[Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Giuliano, F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Giuliano, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?